Cancer Cell Journal Citation Rate 2026
1535-6108
eISSN 1878-3686
Elsevier
NL
Q1 Quartile Top Tier Verified Publisher
About Cancer Cell
Cancer Cell (CC) is a peer-reviewed academic journal covering CAR-T cell therapy research and Cancer Genomics and Diagnostics, published by Elsevier in NL, catalogued under ISSN 1535-6108 (e-ISSN 1878-3686). As of 2026, it has a 2024 2-Year Citation Rate (OpenAlex) of 64.50 (Q1 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It operates a subscription model. OpenAlex records 4,260 works and 901,509 citations, with an h-index of 486.
Authors typically receive a first decision in around 51 days.
Cancer Cell Citation Rate 2026 — In Context
Cancer Cell has a 2024 2-Year Citation Rate (OpenAlex) of 64.50, placing it in the Q1 quartile within the CAR-T cell therapy research research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
Cancer Cell operates a subscription-based publishing model — readers access articles through institutional subscriptions or pay-per-view. Average submission-to-decision turnaround is approximately 51 days — fast by sector standards.
Researchers looking to publish in Cancer Cell should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Cancer Cell against similar journals in the field, use our journal comparison tool.
Submission Tips for Cancer Cell
- The average time from submission to first decision is 51 days, which is moderate for the field.
- This journal covers CAR-T cell therapy research, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Cancer Cell Compares
Compared against 44 journals in the same research areas.
| ISSN (Print) | 1535-6108 |
|---|---|
| ISSN (Online) | 1878-3686 |
| Publisher | Elsevier |
| Country | Netherlands |
| APC / Cost | Inquire with Publisher |
| Review Speed | ~51 days to first decision |
In-depth profile & metrics
Cancer Cell is published by Elsevier and based in Netherlands.
In our subject taxonomy, Cancer Cell is classified under CAR-T cell therapy research, Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers and Cancer-related Molecular Pathways.
For prospective authors, Cancer Cell returns a first decision in about 51 days (moderate for its field).
Its citation rate has held broadly steady over the last 1 years, from 61.275 (2023) to 64.500 (2024).
Research Areas
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Cancer Cell
Live Indexing Status
Updated March 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
The impact factor has remained stable over the last 1 years (from 61.275 to 64.500), reflecting consistent citation performance.
Citation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2024 | 64.500 | 2-Year Mean Citedness (OpenAlex) |
| 2023 | 61.275 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Journal Metrics
Research Highlights
Recently published high-impact papers in this journal:
-
Sugen kinase 495 promotes the proliferation, migration and invasion of lung squamous cell carcinoma cells by targeting Foxo1 transcription factor
Yuanmei Lou, Jun Chen, Yangpeng Tang • 2026
Compare Journals
Compare Cancer Cell against similar publications in its field:
Related Journals in Your Field
-
Aging Cell Wiley IF 64.50
-
Cell Reports Elsevier IF 64.50
-
Cell Death and Disease Springer Nature IF 64.50
-
Cell Death and Differentiation Springer Nature IF 64.50
-
DNA and Cell Biology Mary Ann Liebert IF 64.50
Explore More Journals
Metadata
Last updated: Mar 20, 2026
Updated by: system
Get weekly updates for CAR-T cell therapy research journals
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.